GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR gene editing. Its stock price represents a venture bet on its technology platform for developing cancer cell therapy. The stock price reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Oncology cell gene therapy
Caribou Biosciences is a biotechnology company developing CRISPR genome editing methods to create new cell therapies for oncology. We classify it as "Cell-Gene Therapy for Cancer," one of the most breakthrough areas in medicine. The chart below shows the dynamics of this innovative, yet high-risk, sector.
Broad Market Index - GURU.Markets
Caribou Biosciences is a biotech company, a pioneer in CRISPR genome editing, developing cell therapies for cancer. As a component of the GURU.Markets index, it is at the forefront of science. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CRBU - Daily change in the company's share price Caribou Biosciences
Shares of Caribou, a gene editing company, exhibit extreme volatility, as measured by change_co. This indicator reflects sensitivity to clinical trial results. This metric is a key component of the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Caribou Biosciences, Inc. is a gene editing company. This chart illustrates the extreme volatility of the biotech sector. A comparison with CRBU, a pioneer in CRISPR technology, helps to assess it as a high-risk asset dependent on the success of its platform.
Daily change in the price of a broad market stock, index - GURU.Markets
Caribou Biosciences is a pioneer in using CRISPR genome editing technology to develop cell-based cancer therapies. The company's shares are a bet on this scientific revolution. Their extreme, data-driven volatility is part of the dynamic of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Caribou Biosciences
Caribou Biosciences' year-to-date performance is a story of developing a new generation of cancer cell therapy. Its 12-month market cap is entirely dependent on clinical trial data for its "off-the-shelf" CAR-T cells, created using CRISPR technology. These positive results are fundamental validation of its approach, which promises to make this treatment more accessible.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Caribou Biosciences, Inc. is a biotechnology company pioneering the development of next-generation CRISPR gene editing technologies. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Caribou, a pioneer in CRISPR gene editing, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Caribou Biosciences
Caribou Biosciences (Oncology cell gene therapy) is a pioneer in gene editing (CRISPR). The Perf_Month_Co chart reflects how preclinical and clinical trial cycles, technological breakthroughs, and patent announcements impact its highly volatile, yet promising, medium-term valuation.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
This chart reflects the dynamics of the cutting-edge genetic engineering sector. For Caribou, a pioneer in the field of CRISPR, it's the backdrop. Its volatile movements demonstrate how investor expectations related to breakthrough clinical data and technology news influence the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Caribou Biosciences is a pioneer in genome editing, developing a new generation of CAR-T cell therapy based on CRISPR technology. This is a revolutionary but high-risk field. The overall market has little impact on Caribou; its shares are driven by news of clinical trials, and a single success could trigger explosive growth, defying any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Caribou Biosciences
Caribou Biosciences is a biotechnology company developing cell therapies based on CRISPR gene editing technology. Its weekly stock price is highly volatile, driven by news of clinical trials and technological breakthroughs.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. The company's stock is a bet on a technological revolution in medicine. The chart will show how much its performance is driven by scientific breakthroughs rather than general trends in the healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Caribou is a pioneer in the field of genome editing. The company's shares are a bet on a technological revolution in medicine. The chart will show their extreme volatility and complete detachment from market trends, as they are driven by scientific news.
Market capitalization of the company, segment and market as a whole
CRBU - Market capitalization of the company Caribou Biosciences
Caribou Biosciences' market capitalization reflects its leadership in CRISPR gene editing. Its high market valuation is based on the potential of its platform to create advanced cell therapy for cancer. This is a high-risk bet that its technology will prove more effective and safer than its competitors.
CRBU - Share of the company's market capitalization Caribou Biosciences within the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. Its market share reflects the potential of its cutting-edge platform. The chart is a venture bet that its next-generation technology will offer more effective and safer treatments.
Market capitalization of the market segment - Oncology cell gene therapy
The chart below shows the overall value of the biotech sector. Caribou Biosciences is a pioneer in CRISPR genome editing, founded by one of its inventors. The company is developing a new generation of cell therapies. Its performance against the market reflects a bet that its more precise CRISPR technology will lead to safer and more effective drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies for cancer treatment. Its market cap is a bet on a breakthrough in this technology. The chart below shows the economic weight of the genetic engineering sector.
Book value capitalization of the company, segment and market as a whole
CRBU - Book value capitalization of the company Caribou Biosciences
Caribou's book value is derived from its cutting-edge scientific platform based on CRISPR technology for creating genetically engineered cell therapies. The chart tells the story of a biotech company at the cutting edge of science, investing its capital in developing "off-the-shelf" (allogeneic) cancer treatments that could revolutionize medicine.
CRBU - Share of the company's book capitalization Caribou Biosciences within the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing. The chart shows its share of actual R&D assets. These are its laboratories where a new generation of cell therapies is being developed that can fight cancer with greater precision and safety.
Market segment balance sheet capitalization - Oncology cell gene therapy
Caribou Biosciences is a pioneer in gene editing. Its value lies in its patents and scientific discoveries, not its factories. The chart below reflects the enormous capital intensity of the pharmaceutical sector, demonstrating how lightweight its business model is.
Book value of all companies included in the broad market index - GURU.Markets
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies. The company's assets lie in its unique technology. A small stake in BCap_All provides the foundation for the creation of "living drugs" that could be safer and more effective.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Caribou Biosciences
Caribou Biosciences is a genetic engineering company. Its huge market capitalization is a premium to its cash flow, betting on its cutting-edge CRISPR genome editing platform, which may be more precise than its competitors.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Caribou Biosciences is a biotech company developing CRISPR gene editing. Its value is based almost entirely on its next-generation scientific platform. The chart shows the significant premium to book value that investors are paying for its technological advantage.
Market to book capitalization ratio for the market as a whole
Caribou Biosciences is a pioneer in next-generation genome editing (CRISPR-Cas12a). Its entire value lies in its cutting-edge scientific platform for developing cell therapies. This chart shows the extreme premium investors are willing to pay for this potentially revolutionary technology, ignoring traditional assets.
Debts of the company, segment and market as a whole
CRBU - Company debts Caribou Biosciences
Caribou Biosciences, a pioneer in CRISPR genome editing, is raising significant capital to finance its cutting-edge platform. The debt burden reflects the enormous costs of developing and conducting clinical trials for its allogeneic (donor-derived) CAR-T and CAR-NK cell therapies, which is one of the most capital-intensive areas in biotech.
Market segment debts - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer treatment. This is one of the most advanced and capital-intensive areas of biotechnology. This chart shows how the company funds its expensive research while remaining at the forefront of medical science.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR genome editing, using it to develop cell therapies for cancer. This is a highly research-intensive and costly field. This chart shows the company's reliance on debt to finance its revolutionary but risky research, a key financial indicator.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. This chart shows debt trends in the biotech sector. It helps assess how the company finances its cutting-edge, capital-intensive research and how its financial model compares to other players in the revolutionary CRISPR field.
Debt to book value of all companies in the market
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. This cutting-edge science requires massive investment with no commercial revenue. This total debt chart clearly demonstrates how far Caribou's financial world is removed from the traditional economy. Its survival depends on investors' faith in the technology, not its ability to service its loans.
P/E of the company, segment and market as a whole
P/E - Caribou Biosciences
Caribou Biosciences is a biotech company pioneering CRISPR genome editing. This chart reflects the high investor expectations for its next-generation cell therapy platform. The company's valuation is a bet on a future revolution in cancer treatment, not current profits.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average valuation for biotech companies, providing context for Caribou Biosciences. It reflects generally high valuations based on hopes for breakthroughs. Comparisons with this chart help us understand whether Caribou's cutting-edge CRISPR gene-editing technology is considered more powerful and promising than its competitors in this hot field.
P/E of the market as a whole
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. The company's valuation is a bet on a technological revolution in medicine. This chart of overall biotech risk appetite shows whether investors are willing to pay for the potential of Caribou's platform, which may only be realized many years from now.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Caribou Biosciences
Caribou Biosciences is a biotech company developing CRISPR-based genomic therapies. This chart reflects speculative expectations for a breakthrough in gene editing. The valuation depends entirely on the results of clinical trials of its cell therapy for cancer treatment and confidence in the long-term potential of its technology platform.
%20P%2FE%20Caribou%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Caribou-Biosciences&v=1772662426326 "Chart of the company's future (projected) P/E Caribou Biosciences")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Caribou Biosciences is a biotech company pioneering CRISPR genome editing. This chart reflects investor expectations for the company's profitability relative to the sector. It provides an assessment of the market's confidence in its next-generation platform and its potential for developing cell therapies for cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772662426329 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. For a company operating at the cutting edge of science, this market risk appetite curve is vital. Funding for breakthrough but capital-intensive research directly depends on investors' willingness to invest in long-term, high-risk projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772662426333 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. This chart shows the financial health of the company, which is at the cutting edge of genetic technology.
Profit of companies in the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. This chart shows profitability in the oncology sector. For CRBU, this reflects their belief in the potential of CRISPR to create more effective and durable treatments. Their technology has the potential to overcome the limitations of existing cell therapies.
Overall market profit
Caribou Biosciences is a pioneer in CRISPR genome editing. The company is developing a new generation of cell therapy (CAR-T) for the treatment of advanced cancers. This is cutting-edge science, and its valuation is based on the technology's potential. The overall economic trends reflected in this chart are secondary to scientific breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies for cancer. The profit projections presented here are speculative and depend on the success of its unique chRDNA technology in clinical trials. This is a bet on the next step in the CRISPR revolution.
%20profit%20of%20the%20company%20Caribou%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Caribou-Biosciences&v=1772662426390 "Graph of future (projected) profit of the company Caribou Biosciences")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. The revenue forecast for this cutting-edge segment hinges on the success of this revolutionary technology. This chart reflects analysts' belief that genome editing will become a powerful tool in oncology and will lead to commercial success.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772662426412 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Caribou Biosciences is a biotechnology company pioneering CRISPR genome editing. It is developing cell therapies for cancer treatment. The market profit forecasts shown here reflect the overall investor appetite for risk, which is necessary to fund revolutionary but long-term scientific platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772662426424 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR genome editing, developing cell therapies for cancer. This chart shows a high speculative valuation. Investors are betting on the potential of its cutting-edge technology to create more effective and safe treatments, valuing future breakthroughs rather than current revenue.
P/S market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies for cancer and other diseases. This is one of the most advanced technologies in medicine. This chart shows the average revenue estimate in the biotech sector, which helps us understand the significant premium the market is paying for Caribou's breakthrough platform.
P/S of the market as a whole
Caribou Biosciences is a biotech company, a pioneer in CRISPR genome editing, developing cell therapies for cancer treatment. The company is in clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Caribou Biosciences
Caribou Biosciences is a biotech company using cutting-edge CRISPR genome editing technology to develop new cancer treatments. This chart shows how the market values the company based on its future revenue potential. It reflects the company's enormous potential for breakthroughs in cell therapy.
%20P%2FS%20Caribou%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Caribou-Biosciences&v=1772662426483 "The graph of the company's future (projected) P/S Caribou Biosciences")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing a new generation of cell therapy for cancer. Its technology promises greater precision and efficacy. This chart reflects investor expectations for its cutting-edge science and its potential to become a leader in genetic engineering.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772662426503 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Caribou Biosciences is a biotech company using CRISPR gene editing technology to develop cell-based cancer therapies. This is a cutting-edge and risky field. This market optimism is vital for CRBU. Raising massive amounts of capital for such breakthrough research is only possible with a high investor appetite for risk.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772662426591 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Caribou Biosciences
Caribou Biosciences is a clinical-stage biotechnology company pioneering next-generation CRISPR genome editing for cancer cell therapy. The company currently has no sales revenue. This graph will show the future commercial potential of its cutting-edge gene editing technology.
Sales of companies in the market segment - Oncology cell gene therapy
Caribou Biosciences is a biotechnology company pioneering the use of CRISPR genome editing technology to create a new generation of cell therapies for cancer treatment. Their approach enables the creation of ready-to-use drugs from donor cells. Currently in clinical development, the company has no commercial revenue.
Overall market sales
Caribou Biosciences is a biotechnology company pioneering CRISPR genome editing. It develops next-generation cell therapies for the treatment of cancer and other serious diseases. This revenue chart includes the innovative healthcare sector, where CRBU operates with some of the most advanced technologies in modern science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Caribou Biosciences
Caribou Biosciences is a leading company in the field of CRISPR genome editing. It develops allogeneic (donor-derived) cell therapies for cancer treatment. This chart reflects analysts' confidence in its technology platform and ability to create effective, off-the-shelf drugs.
%20sales%20of%20the%20company%20Caribou%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Caribou-Biosciences&v=1772662426630 "Schedule of future (projected) sales of the company Caribou Biosciences")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies for cancer. This chart shows forecasts for the advanced genetic engineering market. It reflects the enormous expectations for the development of CRISPR technologies, which could lead to safer and more effective treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772662426648 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Caribou Biosciences, a pioneer in CRISPR genome editing, sees this chart as a reflection of investment interest in breakthrough technologies. The stable economic growth predicted here allows investors to finance long-term, capital-intensive biotech projects. This is critical for the development of next-generation cell therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772662426670 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Caribou Biosciences
Caribou Biosciences is a biotech company pioneering CRISPR genome editing. It develops cell therapies for cancer treatment. Being in the R&D stage, it incurs significant expenses. This chart illustrates the investment in its cutting-edge scientific platform, which represents the cost of developing potentially revolutionary treatments.
Market segment marginality - Oncology cell gene therapy
Caribou Biosciences is a biotech company using CRISPR gene editing technology to develop cancer cell therapies. This graph reflects the potential of its cutting-edge platform. A future breakthrough will validate the advantages of its approach to creating more effective treatments.
Market marginality as a whole
Caribou Biosciences is a biotechnology company using CRISPR genome editing technology to develop cell therapies for cancer. Its valuation is based on the potential of its cutting-edge scientific platform. This gross profit chart bears no relation to the disruptive biotech world in which Caribou operates.
Employees in the company, segment and market as a whole
Number of employees in the company Caribou Biosciences
Caribou Biosciences is a pioneer in CRISPR genome editing, developing next-generation cell therapies for cancer. This graphic shows a team of leading scientists using cutting-edge CRISPR technologies to create more powerful and resilient CAR-T and CAR-NK cells that can more effectively fight tumors.
Share of the company's employees Caribou Biosciences within the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing, developing a new generation of cell therapies for cancer treatment. This breakthrough technology requires a team of the world's best genetic engineering scientists. This chart shows the concentration of elite scientific talent, reflecting the company's position at the forefront of biomedical innovation.
Number of employees in the market segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR genome editing. The company is using this revolutionary technology to develop a new generation of cancer cell therapy. This graphic shows an elite team of genetic scientists working to create "off-the-shelf" (allogeneic) cell therapies that could make this treatment more accessible.
Number of employees in the market as a whole
Caribou Biosciences is a biotechnology company pioneering CRISPR genome editing for cell therapy. Their cutting-edge research requires significant capital. The overall economic environment, reflected in the employment graph, influences the availability of this capital. A stable economy encourages venture capital investment in breakthrough technologies like those developed by Caribou.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Caribou Biosciences (CRBU)
Caribou Biosciences is a biotech company, a pioneer in CRISPR genome editing. This chart represents their valuation of this revolutionary technology. Their astronomical market capitalization per employee reflects the market's belief that their platform will transform medicine. The company's value reflects the technology's potential, which is being developed by a small team of brilliant scientists.
%20of%20the%20company%20Caribou%20Biosciences%20(CRBU)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Caribou-Biosciences-CRBU&v=1772662426957 "Chart of market capitalization per employee (in thousands of dollars) of the company Caribou Biosciences (CRBU)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Caribou Biosciences is a biotech company using CRISPR gene editing technology to develop cell therapies for cancer. Its market cap reflects investor confidence in its cutting-edge scientific platform. This chart shows how the market values its innovation potential per employee compared to other companies in the sector.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772662426977 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Caribou Biosciences is a biotechnology company pioneering CRISPR genome editing. This metric reflects the immense value of its cutting-edge technology. Its high market capitalization per employee reflects investors' appreciation of the potential of its platform for creating a new generation of cell therapies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772662427006 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Caribou Biosciences (CRBU)
Caribou Biosciences is a biotech company, a pioneer in genome editing (CRISPR), focused on cancer cell therapy. This graph is negative. The company is a pure R&D operation, founded by a Nobel laureate. Its entire staff consists of scientists, dedicating capital to developing the next generation of CAR-T.
%20Chart%20Caribou%20Biosciences%20(CRBU)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Caribou-Biosciences-CRBU&v=1772662427037 "Company Profit Per Employee (in thousands of dollars) Chart Caribou Biosciences (CRBU)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Caribou Biosciences is a biotech company pioneering CRISPR genome editing. They are developing "allogeneic" (donor-derived) CAR-T therapy for cancer treatment. This graph represents an industry benchmark. For a company at the forefront of genetic engineering, it serves as a benchmark, demonstrating the economic potential the sector aspires to if their sophisticated platform is successful.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772662427049 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Caribou Biosciences is a biotech company, a pioneer in CRISPR gene editing. They are developing next-generation cell therapy (CAR-T) for cancer treatment. This is cutting-edge R&D. The graph shows the enormous investment (negative profit) per scientist working on this complex technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772662427074 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Caribou Biosciences (CRBU)
Caribou Biosciences is a biotechnology company pioneering CRISPR genome editing. This graph reflects the company's advanced research stage. Potentially huge future revenue per employee will come from the development and licensing of cell therapies for cancer and other diseases, which could revolutionize medicine.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Caribou-Biosciences-CRBU&v=1772662427090 "Sales chart per company employee Caribou Biosciences (CRBU)")
Sales per employee in the market segment - Oncology cell gene therapy
Caribou Biosciences (CRBU) is a biotech company using CRISPR (genome editing) technology to develop cell-based cancer therapies. This company is at the cutting edge of R&D, but is in very early stages. The company has no commercial revenue. This chart shows the "cost" of innovation: a large R&D staff but zero sales, which contrasts sharply with the industry average.
Sales per employee for the market as a whole
Caribou Biosciences is a biotech company working at the cutting edge of science. They use CRISPR gene editing technology to create cell therapy (CAR-T) for cancer treatment. This is pure R&D. This graph will likely show zero revenue, as their team of scientists does not yet have a commercial product.
Short shares by company, segment and market as a whole
Shares shorted by company Caribou Biosciences (CRBU)
Caribou Biosciences (CRBU) is a biotech company and a pioneer in CRISPR gene editing. They are developing a cell therapy (CAR-T) for cancer treatment. This chart shows bearish bets. The high short interest reflects investor concerns about the safety and longevity of their allogeneic CAR-T cells or the extremely high competition in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Caribou-Biosciences-CRBU&v=1772662427109 "Short Shares Chart for the Company Caribou Biosciences (CRBU)")
Shares shorted by market segment - Oncology cell gene therapy
Caribou (CRBU) is a biotech company using gene-editing technology (CRISPR) to create CAR-T and CAR-NK cell therapies for cancer treatment. This chart illustrates the general skepticism in the cell therapy sector, reflecting the enormous risks and investor doubts about the success of this cutting-edge technology.
Shares shorted by the overall market
Caribou (CRBU) is a biotech company focused on gene editing (CRISPR). It's one of the most advanced and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off profitless "research projects" en masse, like CRBU, to invest in assets that generate cash here and now.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Caribou Biosciences (CRBU)
Caribou Biosciences is a pioneer in CRISPR genome editing, using it to develop "allogeneic" CAR-T cancer therapy. This is a highly speculative R&D bet. This chart measures the level of hype. It shows when data euphoria (overbought) or platform doubts (oversold) peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Caribou-Biosciences-CRBU&v=1772662427141 "RSI 14 indicator chart for the company's stock Caribou Biosciences (CRBU)")
RSI 14 Market Segment - Oncology cell gene therapy
Caribou Biosciences is a pioneer in CRISPR gene editing. They use this technology to create "allogeneic" (universal) CAR-T cell therapies for cancer treatment. This chart reflects the general sentiment in the genetic engineering sector and helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Caribou (CRBU), a company engaged in "genome editing," is on the rise. This chart is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and CRBU risks running out of funds for its research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRBU (Caribou Biosciences)
Caribou (CRBU) is a biotech company developing cell therapy (CAR-T) based on CRISPR gene editing technology. This chart shows the average target price. It reflects analysts' belief in the technological advantage of Caribou's platform and its clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRBU-Caribou-Biosciences&v=1772662427158 "A chart showing analyst consensus forecasts for the expected stock price. CRBU (Caribou Biosciences)")
The difference between the consensus estimate and the actual stock price CRBU (Caribou Biosciences)
Caribou Biosciences is a pioneer in the CRISPR field. The company is developing "allogeneic" (universal) CAR-T cell therapy, which promises to be safer and more accessible. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this breakthrough technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRBU-Caribou-Biosciences&v=1772662427160 "A chart showing the difference between the consensus forecast and the actual stock price. CRBU (Caribou Biosciences)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Caribou Biosciences is a biotech company, a pioneer in gene editing (CRISPR), developing allogeneic CAR-T cells for cancer treatment. This chart shows general expectations for the cell therapy sector. It reflects whether experts believe in allogeneic cells or believe the future lies with personalized (automated) cells.
Analysts' consensus forecast for the overall market share price
Caribou Biosciences is a biotech company operating at the cutting edge of science. They use CRISPR (genome editing) to create off-the-shelf cell therapies for cancer treatment. This chart shows overall market sentiment. For Caribou, a science-based startup, it's important to understand how risk appetite (sentiment) influences funding for their revolutionary R&D. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Caribou Biosciences
Caribou Biosciences is a pioneer in gene editing, using next-generation CRISPR (chRDNA) technology. They are developing allogeneic (universal, off-the-shelf) CAR-T cell therapies for cancer treatment. This chart is a clear indicator of faith in their cutting-edge science. It reflects the market's appreciation of their clinical data and their technological advantage over competitors.
AKIMA Market Segment Index - Oncology cell gene therapy
Caribou Biosciences is a biotechnology company using advanced CRISPR (chRDNA) genome editing technology to create ready-to-use (allogeneic) CAR-T cells for cancer treatment. This chart shows the average index for the cell therapy sector. It helps investors assess how Caribou's innovative platform compares to the industry average.
The AKIM Index for the overall market
Caribou Biosciences is a leader in CRISPR genome editing (chRDNA technology). It develops off-the-shelf cell therapies. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this cutting-edge scientific platform.
